Shots: :stohththShots: The companies intend to establish manufacturing suites at Lonza’s facilities in the US and Switzerland to manufacture mRNA-1273 at both sites. The collaboration will deploy Lonza’s global expertise in technology transfer and manufacturing while the technology transfer expected to begin in Jun’2020 The focus of the collaboration is to enable the manufacturing of […]Read More
Shots: Pevail and Lonza to work collaboratively for process and analytical development plus large-scale production using the baculovirus/Sf9 process for late-stage clinical and commercial supply at Lonza’s GMP facility in Houston. Lonza to manufacture Prevail’s pipeline of novel AAV-based gene therapy programs for neurodegenerative diseases at its gene therapy center of excellence in Houston, TX […]Read More
Shots: Celltrion has picked to manufacture its biosimilar Remsima’s drug substance at Lonza’s Singapore facility to supply it in American and European markets following its approval in the EU and the US The focus of the agreement is to diversify Celltrion’s biosimilar supply base and meet the increasing demands of the biosimilar market. In H1’19, […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
